EU Insurers Propose Solvency II Rule Changes to Unlock Venture Capital Investment
European insurers have formally proposed amendments to Solvency II rules aimed at freeing up capital for venture capital investment, according to a Law360 report. The industry push targets the calibration of capital charges that currently make VC allocations prohibitively expensive for regulated insurers. The proposals represent a distinct regulatory-reform angle from the broader EU competitiveness debate: rather than lobbying Brussels on macroeconomic agenda-setting, insurers are targeting the granular prudential capital framework that governs how they must hold reserves against equity risk. Under Solvency II's standard formula, unlisted equity — including VC — attracts a stress charge of 49%, making such investments capital-intensive relative to listed assets. Industry bodies argue that recalibrating this charge, or expanding the qualifying criteria for the lower-charge long-term equity sub-class, would materially shift insurer appetite toward growth-stage private companies. The timing is deliberate: the EU's Capital Markets Union agenda explicitly identifies institutional investors as a critical source of scale-up financing for European tech firms. Whether the European Commission incorporates any recalibration into the next Solvency II delegated act revision remains to be seen.
Why this matters
Solvency II capital charges are a structural barrier to European insurers acting as the deep-pocketed VC backers that US and Asian peers sometimes are — any recalibration would redirect material sums into growth-stage equity without requiring public subsidy. The proposal lands within the Capital Markets Union policy frame, giving it political tailwinds, but the European Commission must weigh investor-protection concerns against competitiveness goals. A delegated act change is technically within the Commission's remit and does not require full legislative co-decision, lowering the procedural bar but not eliminating political friction. If adopted, the change would affect asset-allocation mandates, fund structuring advice, and the regulatory-capital opinions that law firms provide to insurer clients across the EU.
On the Ground
Trainees in insurance regulatory or funds practices should note how prudential capital rules intersect with asset-management mandates — a client insurer asking whether a VC fund qualifies as 'long-term equity' under Solvency II is a live instruction type. Flag this development when reviewing investment policy statements or drafting regulatory capital opinions for insurer clients.
Interview prep
Soundbite
Solvency II's equity stress charge is the hidden tax on European venture capital.
Question you might get
“How does the Solvency II standard formula currently treat venture capital investments, and what specific rule change are EU insurers proposing?”
Full answer
Under Solvency II's standard formula, unlisted equity carries a 49% stress charge, making VC allocations capital-intensive for regulated insurers. Industry bodies are pushing to either recalibrate that charge or expand the long-term equity sub-class, which attracts a lower 22% charge. The regulatory hook is the Capital Markets Union agenda, which identifies institutional investors as essential for scaling European tech companies. Any change would come through a delegated act revision — technically within the Commission's remit — but requires balancing policyholder-protection objectives against competitiveness goals. If it proceeds, the impact on insurer asset allocation and fund structuring advice could be significant.
Sources
My notes
saved